Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape.
OHSU researchers discovered a new blood test that identifies pancreatic cancer early on with 85% accuracy when done alongside the current CA 19-9 test.
ZME Science on MSN15h
A Simple Blood Test Called PAC-MANN Could Detect Pancreatic Cancer Early and Save Thousands of LivesA new study from researchers at the Oregon Health and Science University (OHSU) proposes a test called PAC-MANN, which could ...
Pancreatic cancer remains one of the most challenging tumors to treat, partly because it is often discovered at advanced ...
Medical Device Network on MSN45m
Tumour-on-chip model could help discover pancreatic cancer therapiesProfessor Teusch and Dynamic42 set out their work in one of the most challenging cancers, with PDAC being the most common and lethal form of pancreatic cancer. A major cause of it ...
According to the American Cancer Society, people diagnosed with pancreatic cancer have a 13% chance of living five years ...
16h
Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate at the H.C.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback